#USA #Leesburg #Clinical Solutions #Creapharm Bioservices #Resonant Clinical

Resonant Clinical Solutions Expands Capabilities with Creapharm Acquisition

In an impressive move within the life sciences sector, Resonant Clinical Solutions has announced the acquisition of Creapharm Bioservices, a prominent biobanking service provider based in France. This strategic acquisition is part of Resonant's commitment to enhancing its capabilities in delivering advanced therapies and specialized cryogenic storage solutions aimed at supporting increasingly complex clinical trials.

Founded with the mission to support life science organizations across the clinical supply chain, Resonant's acquisition of Creapharm not only enriches its service offerings but also significantly strengthens its posture in the arena of clinical research. Creapharm is well-known for its expertise in biobanking, providing essential services such as cryogenic storage at temperatures as low as -196 °C, an essential requirement for preserving sensitive biological materials used in advanced therapy medicinal products (ATMP).

Expansion of Biobanking Services

Through this acquisition, Resonant aims to broaden its operational footprint in Europe, directly responding to the growing demand for specialized biobanking services. According to a report by IQVIA in August 2025, non-small molecule drugs, particularly advanced modalities, accounted for 46% of phase I to III clinical trials initiated in 2024, which has increased from 38% just five years earlier. This trend underscores the necessity for biorepositories that can manage and safeguard these complex and sensitive materials effectively.

Christophe Berthoux, CEO of Resonant Clinical Solutions, emphasized the increasing need for life sciences companies to partner with specialized providers capable of offering the essential infrastructure and expertise to navigate the complexities of clinical trial lifecycles. He stated, “Creapharm Bioservices significantly amplifies our ability to support clients in developing delicate and complex therapies, while perfectly complementing our current suite of biobanking services.”

Enhancing Client Support

Creapharm’s addition to Resonant's team brings valuable expertise in cold storage and the handling of genetically modified organisms (GMOs), further enhancing the service capabilities available to their clientele. The firm’s facilities adhere to stringent standards of Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), reflecting their commitment to high-quality service delivery.

Corey Stone, Vice President and General Manager of Biobanks at Resonant, highlighted the advanced capabilities Creapharm brings to the table, allowing for a broader range of services that cater to increasingly sensitive materials involved in clinical research. This merger is also anticipated to synergize the existing frameworks in place, enhancing Resonant’s goal to support extensive portions of the clinical trial lifecycle globally.

Strategic Objectives

Myonex, the parent company of Creapharm, is enthusiastic about the transaction, noting that this strategic alignment allows them to concentrate on their core strengths. Greg Lavin, Myonex’s CEO, remarked, “Creapharm Bioservices fits perfectly with Resonant, with specialized experience that complements Resonant's global Biobanks offering.”

The financial details of the acquisition have not been disclosed, but the market analysts view this acquisition as a significant milestone for Resonant, with substantial implications for future clinical trials and biobanking operations.

Resonant Clinical Solutions has built a solid reputation in the life sciences domain, aiding clients in managing the intricacies associated with clinical trials through its over 850 employees who have facilitated more than 2,500 clinical trials and managed upwards of 100 million research assets globally. The future of Resonant looks promising as it continues to empower its partners with comprehensive global solutions that mitigate complexity, ultimately allowing researchers to focus on scientific advancements and patient care.

For further details about their offerings and capabilities, visit resonantclinical.com.